trivalent p2vp8 subunit rotavirus vaccine
Vaccineexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2012 (NCT01738074)
Timeline
Indications
Mechanism of action
- RotavirusImmunity, active
Rotavirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- p2-vp8 subunit rotavirus vaccine
- trivalent p2vp8 subunit rotavirus vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05621655 | Phase 2 | Nov 30, 2022 | Government of China, MAXVAX Biotechnology Limited Liability Company |
| NCT02646891 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2016 | PATH, University of the Witwatersrand |
| NCT02109484 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2014 | PATH |
| NCT01764256 | Phase 1 | Dec 1, 2012 | Johns Hopkins University, PATH |
| NCT01738074 | Phase 3 | Aug 1, 2012 | Government of China |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PATH | Academic/Hospital | 3 | 3 | 2 | 2012 |
| Government of China | Government | 2 | 1 | 2 | 2012 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| MAXVAX Biotechnology Limited Liability Company | For profit | 1 | 1 | 1 | 2022 |
| University of the Witwatersrand | Academic/Hospital | 1 | 0 | 1 | 2016 |
5 organizations
Page 1 / 1